UNRESECTABLE MALIGNANT SOLID NEOPLASM

This early-phase study tests a combination of two drugs (trastuzumab deruxtecan and azenosertib) in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and…

This early-phase trial is testing two experimental drugs, peposertib and tuvusertib, together in people with advanced solid tumors that have spread or cannot be removed. The main goal is to find the safest dose and understand side effects. About 66 adults with specific genetic ch…

This early-phase trial tests two drugs—ZEN003694 and abemaciclib—together in people with advanced NUT carcinoma, breast cancer, or other solid tumors that have spread or can't be removed. The main goals are to find the safest dose and see if the combination can shrink or stabiliz…

This early-stage study tests a new drug called MTI-301 in about 42 adults with advanced solid cancers that have spread or not responded to standard treatments. MTI-301 blocks an enzyme (SCD1) that helps tumors grow. The main goals are to find the safest dose and check for side ef…

This early-phase study tests two drugs, DS-8201a and olaparib, together in people with advanced HER2-positive cancers that have spread or can't be removed. The goal is to find the best dose and see if the combination can shrink or stabilize tumors. About 55 adults with certain so…

This early-stage trial tests the safety and best dose of a new drug called ZEN003694 when given with the standard chemotherapy capecitabine. It is for adults with solid tumors that have spread or can't be removed and have not responded to prior treatments. The goal is to find a d…

This early-stage study tests a new chemotherapy drug, TR-002, in about 52 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. The study also looks at whether the drug can shr…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…

This study tests whether combining two targeted drugs (ZEN003694 and talazoparib) can shrink tumors in people with advanced solid cancers that have spread or cannot be removed. The trial enrolls 88 adults whose cancer no longer responds to standard treatments. Researchers will al…

This early-phase trial tests the safety and best dose of two drugs given together for people with advanced breast cancer or other solid tumors that have a protein called HER2. The drugs are pidnarulex (which stops cancer cells from repairing themselves) and trastuzumab deruxtecan…

This early-phase study tests a drug called novobiocin in people with advanced solid tumors that have specific DNA repair gene mutations (like BRCA). Novobiocin blocks a protein cancer cells need to fix their DNA, causing them to die. The goal is to find the safest dose and see if…

This study screens up to 2,900 people with advanced solid tumors to see if their cancer's genetic makeup can guide them to a targeted combination therapy. Participants must have tried at least one standard treatment. The goal is to learn how well this matching process works and t…